Clinical Rheumatology

, Volume 33, Issue 12, pp 1823–1827 | Cite as

The impact of hepatitis screening on diagnosis and treatment in rheumatoid arthritis

  • Richard Conway
  • Michele F. Doran
  • Finbar D. O’Shea
  • Brendan Crowley
  • Gaye Cunnane
Brief Report

Abstract

Identification of patients with exposure to viral hepatitis is an important part of the care of patients with inflammatory arthritis. This study was conducted to assess the extent of hepatitis B and C screening, and the prevalence of viral hepatitis in a cohort of patients with established rheumatoid arthritis (RA). The medical records of 100 consecutive RA patients were retrospectively analysed for screening of hepatitis B surface antigen, surface antibody and core antibody and hepatitis C antibody. A teaching session was then conducted with the rheumatology team, emphasising the rationale for viral hepatitis testing. We then prospectively analysed 100 more RA patients to see if hepatitis screening improved. In the initial 100 patients (21 % male, mean age 65 years), 85 % were taking methotrexate and 22 % biologic treatments. A complete hepatitis screen was present in 8 %, while 12 % had hepatitis B core antibody checked and 53 % had been tested for hepatitis C.

The second cohort of patients was similar to the first in terms of demographics and treatment. A complete hepatitis screen was available in 63 %, while 65 % had hepatitis B core antibody checked and 81 % had been tested for hepatitis C.

In total, we identified 4 new cases of positive hepatitis B core antibody, 11 cases of positive hepatitis B surface antibody and 1 case of positive hepatitis C antibody. Even in populations where hepatitis B or C is non-endemic, screening will reveal new cases. Educational initiatives are helpful in teaching staff to screen patients.

Keywords

Disease-modifying antirheumatic drugs Immunosuppressive Agents Rheumatoid Arthritis Screening Viral hepatitis 

Notes

Disclosure statement

The authors declare that they have no conflict of interest.

References

  1. 1.
    Calabrese LH, Zein NN, Vassilopoulos D (2006) Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 65:983–989PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Weinbaum CM, Williams I, Mast EE et al (2008) Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 57:1–20PubMedGoogle Scholar
  3. 3.
    Winthrop KL, Calabrese LH (2011) Let the fog be lifted: screening for hepatitis B virus before biological therapy. Ann Rheum Dis 70:1701–1703PubMedCrossRefGoogle Scholar
  4. 4.
    Singh JA, Furst DE, Bharat A et al (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64:625–639CrossRefGoogle Scholar
  5. 5.
    Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRefGoogle Scholar
  6. 6.
    Raimondo G, Pollicino T, Cacciola I, Squadrito G (2007) Occult hepatitis B infection. J Hepatol 46:160–170PubMedCrossRefGoogle Scholar
  7. 7.
    Lan JL, Chen YM, Hsieh TY et al (2011) Kinetics of viral loads and risk of HBV reactivation in HBcAb positive RA patients undergoing anti-TNF-α therapy. Ann Rheum Dis 70:1719–1725PubMedCrossRefGoogle Scholar
  8. 8.
    Urata Y, Uesato R, Tanaka D et al (2011) Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol 21:16–23PubMedCrossRefGoogle Scholar
  9. 9.
    Nardone A, Anastassopoulou CG, Theeten H et al (2009) A comparison of hepatitis B seroepidemiology in ten European countries. Epidemiol Infect 137:961–969PubMedCrossRefGoogle Scholar
  10. 10.
    Thornton L, Murphy N, Jones L et al (2012) Determination of the burden of hepatitis C virus infection in Ireland. Epidemiol Infect 140:1461–1468PubMedCrossRefGoogle Scholar
  11. 11.
    IOM (Institute of Medicine) (2010) Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. The National Academies Press, Washington, DCGoogle Scholar
  12. 12.
    Balogun MA, Ramsay ME, Hesketh LM et al (2002) The prevalence of hepatitis C in England and Wales. J Infect 45:219–226PubMedCrossRefGoogle Scholar
  13. 13.
    Gay NJ, Hesketh LM, Osborne KP, Farrington CP, Morgan-Capner P, Miller E (1999) The prevalence of hepatitis B infection in adults in England and Wales. Epidemiol Infect 122:133–138PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Vassilopoulos D, Apostolopoulou A, Hadziyannis E et al (2010) Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 69:1352–1355PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2014

Authors and Affiliations

  • Richard Conway
    • 1
  • Michele F. Doran
    • 1
  • Finbar D. O’Shea
    • 1
  • Brendan Crowley
    • 2
  • Gaye Cunnane
    • 1
    • 3
  1. 1.Department of RheumatologySt. James HospitalDublinIreland
  2. 2.Department of MicrobiologySt. James HospitalDublinIreland
  3. 3.Department of Clinical MedicineTrinity CollegeDublinIreland

Personalised recommendations